Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus.
Identifieur interne : 000726 ( Ncbi/Curation ); précédent : 000725; suivant : 000727Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus.
Auteurs : Amy C. Shurtleff [États-Unis]Source :
- IDrugs : the investigational drugs journal [ 1369-7056 ] ; 2004.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (pharmacologie), Adjuvants immunologiques (usage thérapeutique), Anti-infectieux (pharmacologie), Anti-infectieux (usage thérapeutique), Bioterrorisme, Humains, Immunisation passive, Immunothérapie, Petit ARN interférent (génétique), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (épidémiologie), Vaccins à ADN (usage thérapeutique).
- MESH :
- génétique : Petit ARN interférent.
- immunologie : Syndrome respiratoire aigu sévère.
- pharmacologie : Adjuvants immunologiques, Anti-infectieux.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Adjuvants immunologiques, Anti-infectieux, Vaccins à ADN.
- épidémiologie : Syndrome respiratoire aigu sévère.
- Bioterrorisme, Humains, Immunisation passive, Immunothérapie.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (pharmacology), Adjuvants, Immunologic (therapeutic use), Anti-Infective Agents (pharmacology), Anti-Infective Agents (therapeutic use), Bioterrorism, Humans, Immunization, Passive, Immunotherapy, Infections (drug therapy), RNA, Small Interfering (genetics), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (immunology), Vaccines, DNA (therapeutic use).
- MESH :
- chemical , genetics : RNA, Small Interfering.
- chemical , pharmacology : Adjuvants, Immunologic, Anti-Infective Agents.
- chemical , therapeutic use : Adjuvants, Immunologic, Anti-Infective Agents, Vaccines, DNA.
- drug therapy : Infections, Severe Acute Respiratory Syndrome.
- epidemiology : Severe Acute Respiratory Syndrome.
- immunology : Severe Acute Respiratory Syndrome.
- Bioterrorism, Humans, Immunization, Passive, Immunotherapy.
Abstract
The purpose of this meeting was to provide a forum for expert presentations and discussion about the threats of bioterrorism and emerging infectious diseases, and to address the issues relating to epidemics, prevention of infection and treatment of some of these emerging infectious diseases classified as potential agents of bioterror. Included in the talks were state-of-the-art presentations about infectious clone technology and recombinant viruses, pathogen and receptor interactions at the cellular and molecular level, genomic responses to infection, and new information on antiviral mechanisms of action. Severe acute respiratory syndrome (SARS) and progress toward understanding the epidemic was addressed, and other sessions were presented concerning immune therapy and immunopotentiation of disease, siRNA and gene silencing, host responses to pathogen infections, as well as the use of genetic engineering to circumvent and direct the immune response. Many discussions were held and data were presented about possible compounds and new drugs that may have antiviral properties, yet there were few discussions of any available new drugs. This report addresses reverse genetics of SARS virus, as well as its epidemiology, and a host of different recent approaches to developing antivirals effective against SARS, including some potential vaccine candidates. Also presented are hypotheses about the human immune response to SARS infection, as well as immune therapies against botulinum and anthrax toxins. This report also addresses antiviral approaches exploiting siRNAs, and different aspects of the host immune response to many of the different dangerous pathogens discussed at this meeting. Finally, approaches to circumventing and directing the immune response using genetic engineering will be reported.
PubMed: 15057645
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E72
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002E72
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002E07
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000726
Links to Exploration step
pubmed:15057645Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus.</title><author><name sortKey="Shurtleff, Amy C" sort="Shurtleff, Amy C" uniqKey="Shurtleff A" first="Amy C" last="Shurtleff">Amy C. Shurtleff</name><affiliation wicri:level="2"><nlm:affiliation>US Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, Frederick, MD 21702-5011, USA. amy.shurtleff@det.amedd.army.mil</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>US Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, Frederick, MD 21702-5011</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15057645</idno><idno type="pmid">15057645</idno><idno type="wicri:Area/PubMed/Corpus">002E72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E72</idno><idno type="wicri:Area/PubMed/Curation">002E72</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E72</idno><idno type="wicri:Area/PubMed/Checkpoint">002E07</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E07</idno><idno type="wicri:Area/Ncbi/Merge">000726</idno><idno type="wicri:Area/Ncbi/Curation">000726</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus.</title><author><name sortKey="Shurtleff, Amy C" sort="Shurtleff, Amy C" uniqKey="Shurtleff A" first="Amy C" last="Shurtleff">Amy C. Shurtleff</name><affiliation wicri:level="2"><nlm:affiliation>US Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, Frederick, MD 21702-5011, USA. amy.shurtleff@det.amedd.army.mil</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>US Army Medical Research Institute of Infectious Diseases, Virology Division, Fort Detrick, Frederick, MD 21702-5011</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j">IDrugs : the investigational drugs journal</title><idno type="ISSN">1369-7056</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (pharmacology)</term><term>Adjuvants, Immunologic (therapeutic use)</term><term>Anti-Infective Agents (pharmacology)</term><term>Anti-Infective Agents (therapeutic use)</term><term>Bioterrorism</term><term>Humans</term><term>Immunization, Passive</term><term>Immunotherapy</term><term>Infections (drug therapy)</term><term>RNA, Small Interfering (genetics)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Vaccines, DNA (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (pharmacologie)</term><term>Adjuvants immunologiques (usage thérapeutique)</term><term>Anti-infectieux (pharmacologie)</term><term>Anti-infectieux (usage thérapeutique)</term><term>Bioterrorisme</term><term>Humains</term><term>Immunisation passive</term><term>Immunothérapie</term><term>Petit ARN interférent (génétique)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (épidémiologie)</term><term>Vaccins à ADN (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Anti-Infective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Anti-Infective Agents</term><term>Vaccines, DNA</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Petit ARN interférent</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Anti-infectieux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Anti-infectieux</term><term>Vaccins à ADN</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Bioterrorism</term><term>Humans</term><term>Immunization, Passive</term><term>Immunotherapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Bioterrorisme</term><term>Humains</term><term>Immunisation passive</term><term>Immunothérapie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this meeting was to provide a forum for expert presentations and discussion about the threats of bioterrorism and emerging infectious diseases, and to address the issues relating to epidemics, prevention of infection and treatment of some of these emerging infectious diseases classified as potential agents of bioterror. Included in the talks were state-of-the-art presentations about infectious clone technology and recombinant viruses, pathogen and receptor interactions at the cellular and molecular level, genomic responses to infection, and new information on antiviral mechanisms of action. Severe acute respiratory syndrome (SARS) and progress toward understanding the epidemic was addressed, and other sessions were presented concerning immune therapy and immunopotentiation of disease, siRNA and gene silencing, host responses to pathogen infections, as well as the use of genetic engineering to circumvent and direct the immune response. Many discussions were held and data were presented about possible compounds and new drugs that may have antiviral properties, yet there were few discussions of any available new drugs. This report addresses reverse genetics of SARS virus, as well as its epidemiology, and a host of different recent approaches to developing antivirals effective against SARS, including some potential vaccine candidates. Also presented are hypotheses about the human immune response to SARS infection, as well as immune therapies against botulinum and anthrax toxins. This report also addresses antiviral approaches exploiting siRNAs, and different aspects of the host immune response to many of the different dangerous pathogens discussed at this meeting. Finally, approaches to circumventing and directing the immune response using genetic engineering will be reported.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000726 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000726 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:15057645
|texte= Bioterrorism and emerging infectious disease - antimicrobials, therapeutics and immune-modulators. SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:15057645" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |